Pilgrim Partners Asia Pte Ltd Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Pilgrim Partners Asia Pte Ltd bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,600 shares of the medical device company's stock, valued at approximately $513,000.

Several other large investors have also recently bought and sold shares of the company. Watts Gwilliam & Co. LLC bought a new stake in DexCom in the fourth quarter worth about $3,334,000. Congress Asset Management Co. raised its position in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of DexCom by 2,226.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after purchasing an additional 222,548 shares during the last quarter. First Hawaiian Bank increased its position in DexCom by 556.1% during the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after buying an additional 19,629 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $5,812,000. 97.75% of the stock is owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last ninety days. Corporate insiders own 0.30% of the company's stock.

Remove Ads

DexCom Trading Up 0.2 %

Shares of NASDAQ:DXCM traded up $0.12 during trading on Thursday, reaching $66.96. 5,100,289 shares of the company were exchanged, compared to its average volume of 4,109,972. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business's fifty day simple moving average is $77.74 and its 200-day simple moving average is $76.63. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $141.25. The firm has a market capitalization of $26.25 billion, a PE ratio of 46.83, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of recent analyst reports. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Finally, Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.